Understanding ATTR-CM starts with understanding its pathophysiology.
Explore expert insights from Dr. Scott Solomon and Dra. Marianna Fontana deepen your knowledge of the mechanisms behind the disease.
Complete a short knowledge check to access the video.
๐ฆWatch now: https://t.co/iKCJPLut8v
The post-KRAS G12C landscape is rapidly evolving.
New agents like elisrasib and zoldonrasib, along with pan-RAS strategies, show that resistance is no longer the end, but the start of a new therapeutic line.
๐ Read the full analysis on our website - https://t.co/02YrNBYkVj
Personalized mRNA vaccines are gaining real momentum in oncology.
With a 49% reduction in recurrence risk in melanoma and expansion into challenging tumors like PDAC and NSCLC, AACR 2026 highlights a major step forward for this approach.
๐ Read the full analysis on our website - https://t.co/WEeD3nsqA6
AI is reshaping oncology and computational pathology is at the center of this transformation.
From foundation models predicting biomarkers directly from H&E to digital twins and spatial AI, AACR 2026 signals a shift from innovation to real clinical application.
๐ Read the full analysis at the link - https://t.co/IgiEKMbjBg
ctDNA is redefining the adjuvant treatment landscape in solid tumors.
With up to a 10-month lead time over clinical relapse, MRD detection creates a real window to act earlier โ before disease becomes clinically evident.
๐ Read the full analysis at the link - https://t.co/rLHcNjMN8E
Cell therapy in solid tumors is entering a new phase.
From KIR-CAR tackling T cell exhaustion to smart armoring and in vivo CAR-T, #AACR2026 marks the shift from experimental to clinically actionable innovation.
Focus now: optimization, combinations, real-world impact.
๐ https://t.co/QP7T9tsGND
Bispecifics enter a new phase: optimization & synergy.
AACR 2026 highlights updated teclistamab data, new targets (GPRC5D, FcRH5) and ADC + BiTE combos.
Focus shifts to sequencing, rational combos & toxicity management.
๐ https://t.co/X7q6WrLASY
ADCs enter the precision 2.0 era.
ORR >60% in hard-to-treat cancers + multi-payload strategies mark a shift from proof of concept to optimization.
Focus now: overcoming resistance & refining sequencing, incl. ADC + IO combos.
๐ https://t.co/CjzvTptGfL
Updated TROPION-Breast01 data position Dato-DXd as a key post-CDK4/6i option in HR+/HER2- metastatic breast cancer.
Improved PFS, manageable toxicity, and roles in HER2-low & combos impact sequencing decisions.
TROP2 & PIK3CA may refine patient selection.
๐ https://t.co/1PsoVzeyGt
A major shift in cervical cancer screening ๐จ
HPV self-collection is now a preferred option โ improving access & boosting participation, especially in underserved groups.
Earlier detection. Higher coverage. Real progress.
๐ https://t.co/6e4VlZfFPG
Obesity, insulin resistance & endometrial cancer are closely linked โ and GLP-1 agonists may impact prevention, treatment & survivorship.
Early data point to a new oncologyโendocrinology frontier.A paradigm shift in the making.
๐ https://t.co/wocNIf5t5S
New data at SGO 2026 ๐จ
Luveltamab tazevibulin (STRO-002) shows efficacy in platinum-resistant ovarian cancer with FRฮฑ โฅ25%, including lowโmoderate expression.
Up to 80โ90% of patients could benefit.
A key advance in precision oncology.
๐ https://t.co/DXzY2Jvf8C
RUBY 4-year data (SGO 2026): dostarlimab shows OS benefit even in pMMR/MSS patients โ supporting its use in 1L regardless of MMR status.
NRG GY-035 marks the next step: smarter combos for high-risk groups like TP53-mutated disease.
https://t.co/vzRpNUNMew
BLUESTAR (SGO 2026) highlights AZD8205โs potential in advanced endometrial cancer โ even post-immunotherapy.
With consistent responses and a high-prevalence target (B7-H4), new paths are emerging beyond checkpoint inhibitors.
Whatโs next for clinical practice?
๐ https://t.co/VSPtDZaGMS
IMGN853-0420 expands mirvetuximabโs role in ovarian cancer.
Strong responses in platinum-sensitive disease move this anti-FRฮฑ ADC earlier in the treatment continuum.
Key insights & clinical impact ๐
๐ https://t.co/qLO4L8Oo2D
GOG-3039 may reshape endometrioid carcinoma treatment.
Promising PFSโespecially in chemo-naรฏve patientsโsupports abemaciclib + letrozole as a chemo-free, oral strategy.
Key data & clinical impact ๐
๐ https://t.co/u0sIF8PsdI
KEYNOTE-B96 is a game changer in ovarian cancer.
First immunotherapy regimen to show OS benefit in platinum-resistant disease โ redefining this setting.
Explore the data and clinical impact ๐
๐ https://t.co/JvVftJTHPI
New insights in complex coronary bifurcation PCI ๐จ
The DKCRUSH VIII trial showed that IVUS-guided PCI significantly reduced target vessel failure compared with angiography alone โ reinforcing the role of intravascular imaging in optimizing outcomes.
๐ Want to dive deeper into the data and clinical implications?
Check out the full analysis at the link - https://t.co/FhCbuA3qFh